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Abstract The N-terminal domains VI plus V (62 kDa) and V
alone (43 kDa) of the laminin K1 chain were obtained as
recombinant products and shown to be folded into a native form
by electron microscopy and immunological assays. Domain VI
alone, which corresponds to an LN module, did not represent an
autonomously folding unit in mammalian cells, however. Frag-
ment K1VI/V, but not fragment K1V, bound to purified K1L1 and
K2L1 integrins, to heparin, and to heparan sulfate-substituted
domains I and V of perlecan. This localized the binding activities
to the LN module, which contains two basic sequences suitable
for heparin interactions.
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1. Introduction
Laminins are ubiquitous basement membrane proteins
which form networks or ¢laments, promote cell adhesion
through integrin and dystroglycan receptors and interact
with other basement membrane proteins such as nidogen,
perlecan and ¢bulin-1 [1]. Eleven distinct isoforms of laminin
have been identi¢ed so far, composed of one of each of ¢ve
di¡erent K, three L and two Q chains in a heterotrimeric as-
sembly [2,3]. Electron microscopy of these chain assemblies
demonstrated a cross- or T-shaped structure in which the
short arms consist of the N-terminal domains of the three
chains. In six of the laminin chains (K1, K2, K5, L1, L2, Q1)
the most N-terminal region (domains VI/V) consists of a lam-
inin-type N-terminal (LN) module followed by a tandem ar-
ray of laminin EGF-like (LE) modules [4]. Together they form
a globular domain connected to a short rod [5] and have been
shown to be crucial elements in the polymerization of certain
laminins into large networks [6^8]. It was also indicated that
the same region of the laminin K1 chain binds to K1L1 and
K2L1 integrins and to heparin [9,10].
In the present study, we have examined the production of
laminin K1 chain domains VI/V by recombinant methods that
have previously been used to successfully localize nidogen
binding to a single LE module in the laminin Q1 chain [11].
This has allowed us to assign integrin, heparin and perlecan
binding to the LN module, which corresponds to domain VI.
Yet it was also shown that the LN module needed to be
connected to LE modules to assure its proper folding.
2. Materials and methods
2.1. Expression vectors and cell transfection
A 1.8 kb XbaI/StuI cDNA fragment encoding the entire N-terminal
region of the mouse laminin K1 chain [12] was used as a template for
ampli¢cation by polymerase chain reaction with Vent polymerase
(Biolabs) following the manufacturer’s instructions. The following
synthetic oligonucleotides were used as primers: primer 1, 5P-GCCC-
CGCTAGCAATGTGCATTTGCTACGGCCAT; primer 2, 5P-GC-
CCCGCTAGCACAGCAGAGAGGCTTGTTCCC; primer 3, 5P-
TCAGTTAGCGGCCGCTCAGCCTCCAACGGAAATGTCTTTT;
primer 4, 5P-TCAGTTAGCGGCCGCTCACTCACACTCGTTGCC-
GGAG; primer 5, 5P-TCAGTTAGCGGCCGCTCAGGAGCAGCC-
CTCGGGGTTT.
Sequences encoding recombinant laminin fragment K1VI were ob-
tained with the primer pair 1/3, fragment K1VI-1 with the pair 1/4,
fragment K1V with the pair 2/4 and fragment K1VI/V with the pair
1/5. These primer combinations introduced a novel NheI site at the
5P end and a stop codon and NotI site at the 3P end. The products
were restricted with NheI and NotI and, after puri¢cation by
agarose gel electrophoresis, were inserted in frame with the BM-40
signal peptide [11] in an expression vector restricted with the same
enzymes. The episomal expression vectors used were pCEP-sh [13] or
pCEP-Pu [14], which contain either the phleomycin or puromycin
resistance genes, respectively. The sequences of the constructs were
veri¢ed by cycle sequencing on a 373A DNA sequencer (Applied
Biosystems).
Human embryonic kidney 293 or 293-EBNA cells were transfected
using lipofectamine (Gibco) as described by the supplier. After anti-
biotic selection, cells were grown either in a Tecnomouse hollow ¢ber
system [15] or in a factory of 10 stacked trays (Nunc). Serum-free
culture medium was then regularly collected for the puri¢cation of
recombinant fragments.
2.2. Protein puri¢cation and modi¢cation
Culture medium (0.1^0.4 l) containing recombinant fragment K1VI/
V was dialyzed against 0.05 M Tris-HCl pH 7.4, 0.1 M NaCl and
passed over a heparin-Sepharose column (2.5U15 ml) equilibrated in
the same bu¡er. Bound fractions were eluted with a linear 0.1^0.6 M
NaCl (600 ml) gradient, concentrated and further puri¢ed on a Se-
pharose CL-6B column [16]. Medium containing fragment K1V was
initially passed over a DEAE cellulose column (2.5U25 cm) which
was equilibrated in 0.05 M Tris-HCl pH 8.6. After eluting with a 0^
0.5 M NaCl gradient (1000 ml), the relevant fractions were further
puri¢ed on a Superose 12 HR 16/50 column (Pharmacia) equilibrated
in 0.2 M ammonium acetate pH 6.9. Degradation with neutral pro-
teases was performed in 0.05 M Tris-HCl pH 7.4 at 37‡C at an
enzyme-substrate ratio of 1:100. A 1 ml heparin HiTrap column
(Pharmacia) equilibrated in 0.05 M Tris-HCl pH 7.4 and eluted
with a linear 0^0 .6M NaCl gradient was used for chromatography
of small protein samples (0.2^1 mg).
Laminin-1, several of its proteolytic fragments and the heparan
sulfate proteoglycan perlecan were prepared from a mouse tumor
[17]. Recombinant perlecan fragments IA [18] and V and Vc [19]
were obtained as described. In addition, we prepared a modi¢ed frag-
ment I (I-Mut) where heparan sulfate attachment was prevented by
Ala mutagenesis of Ser-65, Ser-71 and Ser-76 (T. Sasaki, M. Costell,
R. Timpl, in preparation). A⁄nity-puri¢ed K1L1 integrin from human
placenta and K2L1 integrin from human platelets were those used
previously [9]. Some of these integrins were also kindly supplied by
J. Eble, Muºnster.
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2.3. Binding assays
Solid-phase assays with plastic-immobilized ligands followed a pre-
viously used procedure [20]. Binding was detected with speci¢c anti-
sera raised against perlecan fragments IA and V [18,19]. Surface plas-
mon resonance assays were performed with BIAcore instrumentation
(BIAcore AB, Uppsala) using fragments K1VI/V and K1V immobi-
lized by covalent coupling to CM-5 sensor chips [21]. Binding assays
with perlecan fragments were carried out in 0.05 M Tris-HCl, 0.15 M
NaCl, 0.05% P20 detergent (TBS) and those with integrins in TBS
containing 1 mM MgCl2, 1 mM MnCl2 and 0.1 mM CaCl2. The
divalent cations were replaced by 4 mM EDTA as a control for
speci¢city [9]. Soluble ligands were used in the concentration range
0.3^1 WM and chips were regenerated by spontaneous dissociation
(integrins) or by treatment with saturated NaCl (perlecan). Further
details of the procedure and evaluation of the kinetic constants by the
1:1 model have been previously described [21].
2.4. Analytical and other methods
Samples were hydrolyzed with 6 M or 3 M HCl (16 h, 110‡C) for
the determination of the amino acid or hexosamine contents, respec-
tively, on a LC3000 analyzer (Biotronik). SDS gel electrophoresis
followed standard protocols. Edman degradation on Procise and
473 sequencers (Applied Biosystems) followed the manufacturer’s in-
structions. Mixtures of protein fragments were electrophoretically sep-
arated and blotted onto Immobilon PSQ membranes (Millipore) for
sequencing. Circular dichroism (CD) spectroscopy [22], electron mi-
croscopy after rotary shadowing [23] and immunological assays [24]
followed standard protocols.
3. Results
The N-terminal region of the laminin K1 chain, which cor-
responds to domains VI and V [12] (positions 1^484), consists
of one LN module and a tandem array of four LE modules
(Fig. 1a). Expression vectors designed to express the entire
structure (K1VI/V) or the individual domains K1VI and K1V
were used to transfect mammalian 293 cells. Electrophoresis
of serum-free culture medium demonstrated strong bands of
the expected size for fragments K1VI/V and K1V, but K1VI
was not detected either by protein staining or immunoblot-
ting. A larger vector, K1VI-1, encoding the LN and an adja-
cent LE module (Fig. 1a), was therefore constructed, but this
only gave rise to low production and secretion of a 35 kDa
product, as identi¢ed by immunoblotting. This suggested that
the LN module does not represent an autonomously folding
protein domain and requires additional structures for stabili-
zation.
The high production and secretion of fragments K1VI/V
and K1V (40^180 Wg/ml, as determined by radioimmunoassay)
facilitated their e⁄cient puri¢cation from serum-free culture
medium. Fragment K1VI/V bound quantitatively to a heparin-
Sepharose column and, after molecular sieve chromatography,
appeared as a 62 kDa band when examined by electrophoresis
under non-reducing conditions (Fig. 1b). DEAE cellulose and
molecular sieve chromatography were su⁄cient to obtain the
43 kDa fragment K1V in a pure form. Electrophoresis under
reducing conditions (Fig. 1b) caused a slightly slower migra-
tion for fragment K1VI/V, indicating the opening of internal
disul¢de bridges. In contrast, fragment K1V migrated slightly
faster after reduction, as has previously been observed for a
similar tandem array of LE modules from the laminin Q1
chain [11]. Edman degradation of each fragment demon-
strated a single N-terminal sequence which started with
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Fig. 1. Modular structure of the N-terminal domain VI/V of the
laminin K1 chain (a) and electrophoresis of puri¢ed recombinant
fragments (b) and of an elastase digest of fragment K1VI/V (c). The
structure in a shows the N-terminal laminin-type module (LN) and
laminin-type epidermal growth factor-like (LE) modules with the re-
combinant fragments identi¢ed underneath by their terminal sequen-
ces and position numbers [12]. Each vector also encoded an N-ter-
minal APLA sequence derived from BM-40 [11]. Electrophoresis in
b shows fragments K1V (lanes 1, 2) and K1VI/V (lanes 3, 4) used in
reduced (+) and non-reduced (3) form. c: Elastase digests of frag-
ment K1VI/V which either bind to heparin (lane 1) or lack this
property (lane 2) were examined under non-reducing conditions.
Numbers beside the bands denote starting positions of the major N-
terminal sequence as determined after electroblotting. Calibration of
both electrophoretic runs is indicated in kDa in the left margins.
Fig. 2. Electron micrographs of rotary shadowed recombinant frag-
ments K1VI/V (a) and K1V (b). The bar indicates the magni¢cation
for both parts of the ¢gure.
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APLA derived from the vector and then continued with the
authentic K1 chain sequence shown in Fig. 1a. Fragment
K1VI/V was substituted with 13.5 residues of glucosamine
and 2 residues of galactosamine, which were reduced to 5.5
and 1 residues, respectively, in fragment K1V.
The CD spectra of both fragments were similar to those of
other fragments containing LE models [22], indicating the
presence of K helical and L strand conformation (data not
shown). Rotary shadowing electron microscopy of fragment
K1V revealed short rods of about 10 nm length (Fig. 2b).
Similar rods connected to a small globular domain were ob-
served for fragment K1VI/V (Fig. 2a). A rabbit antiserum
raised against fragment K1VI/V showed a high titer in radio-
immunoassays (1:3U104), as did several antisera against lam-
inin-1 from a mouse tumor. A sensitive radioimmuno-inhib-
ition assay demonstrated almost identical inhibition pro¢les
for fragment K1VI/V and laminin-1 with IC50 = 0.2 nM (Fig.
3). Recombinant fragment K1V and the laminin-1 short arm
fragment E1XNd were also comparable inhibitors, but inhib-
ition was incomplete, with 20^25% residual binding. This in-
dicated antibody binding to epitopes on both the LE and LN
modules. A related fragment E4 from the N-terminus of the
laminin L1 chain (domain VI/V) was, however, only a poor
inhibitor (Fig. 3). The antibodies against fragment K1VI/V
were puri¢ed by a⁄nity chromatography and found to react
strongly with basement membrane zones in immuno£uores-
cence on several frozen mouse tissue sections (data not
shown).
Fragment K1VI/V was shown to have a high a⁄nity for
heparin and could be eluted from an analytical HiTrap col-
umn in a sharp peak at 0.3 M NaCl. The same elution pro¢le
was obtained for laminin fragment E3 from the C-terminal
end of the laminin K1 chain. Fragment K1V, however, as well
as recombinant laminin fragments L1VI/V and Q1VI/V (T.
Sasaki, R. Timpl, unpublished), did not bind to the heparin
column at low ionic strength. Several neutral proteases were
found to cleave recombinant K1VI/V into distinct fragments
which were used for further mapping. A short digestion (1 h)
with pancreatic elastase produced two major bands of V40
kDa which both started at position 225 within the LN mod-
ule. A further band of 34 kDa started with the original N-
terminus (Fig. 1c). All of these bands showed an undiminished
binding to heparin. A more prolonged digestion (24 h) abol-
ished heparin binding. The latter digest contained a major 38
kDa band which started at positions 248/251 just in front of
domain V and a faint 16 kDa band that had lost 13^18 res-
idues from the N-terminus of the LN module (Fig. 1c). Since
this 16 kDa component is considerably smaller than its paren-
tal 34 kDa band, a substantial cleavage must also have oc-
curred at the C-terminus.
Heparin binding of laminin-1 domains has been considered
to correspond to interactions with various heparan sulfate
proteoglycans. A previous study with perlecan, however, dem-
onstrated that only fragment E3 and no other proteolytic
laminin fragment had binding activity [25]. Using solid-phase
assays, we could now demonstrate that perlecan also binds to
fragment K1VI/V with a binding pro¢le distinct from that of
fragment E3 (Fig. 4a). Heparan sulfate attachment to perlecan
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Fig. 4. Binding of perlecan and its heparan sulfate-containing frag-
ments to laminin-1 fragments in solid-phase assays. Soluble ligands
were perlecan (a) and the fragments Vc (b) and IA (c). Immobilized
ligands were the laminin fragments E3 (a), K1VI/V (O) and K1V
(P) and, as a background control, serum albumin (E). In all assays,
binding to serum albumin and K1V was nearly superimposable. Fur-
ther controls included the non-substituted perlecan fragments V (R)
in (b) and I-Mut (R) in (c) using immobilized laminin fragment
K1VI/V as ligand. Detection of binding was with antibodies against
perlecan (a) and its fragments V (b) and IA (c).
Fig. 3. Radioimmuno-inhibition assay for epitopes present in the N-
terminal domain of the laminin K1 chain. The assay consisted of
125I-labeled fragment K1VI/V (1 ng) and a ¢xed concentration of a
rabbit antiserum against the same fragment. Inhibitors used were re-
combinant fragments K1VI/V (a) and K1V (b), laminin-1 (O) and
its fragments E1XNd (F) and E4 (O). Similar pro¢les were ob-
tained with an antiserum against laminin-1 (not shown).
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occurs through its domains I and V, which are located at
opposite ends of the protein core [18,19]. Corresponding re-
combinant perlecan fragments IA and Vc were both shown to
bind to laminin fragment K1VI/V with an a⁄nity comparable
to (Vc, Fig. 4b) or about 10-fold lower (IA, Fig. 4c) than
fragment E3. Neither perlecan nor its two heparan sulfate-
containing fragments showed signi¢cant binding to fragment
K1V. Furthermore, perlecan fragments V (Fig. 4b) and I-Mut
(Fig. 4c), which lack heparan sulfate chains, showed a
strongly reduced binding. Together, the data demonstrate
that binding occurs between the LN module and the heparan
sulfate chains of perlecan. These data were con¢rmed in a
surface plasmon resonance assay, which demonstrated similar
a⁄nities for the interaction between immobilized fragment
K1VI/V and perlecan fragments IA and Vc (Table 1). Here
again, no or only questionable binding was observed with
fragment K1V (data not shown).
Previous studies with puri¢ed K1L1 and K2L1 integrins sug-
gested that they should bind to the N-terminal region of the
laminin K1 chain [9]. This could now be directly demonstrated
in surface plasmon resonance assays with immobilized frag-
ment K1VI/V, which showed a ¢ve-fold di¡erence in its a⁄n-
ity for the two integrins (Table 1). These interactions were
abolished by EDTA and did not occur with fragment K1V,
which underscored the speci¢city of the binding as well as the
involvement of the LN module.
4. Discussion
In the present study we used an established recombinant
expression system in mammalian cells to obtain the N-termi-
nal domain VI/V of the laminin K1 chain (module structure
LNLE4) and domain V alone (LE4) in high yields and purity.
Both recombinant fragments were folded into their native
structure as shown by CD spectroscopy, electron microscopy,
immunological assays and partial resistance to proteolysis.
They were also modi¢ed mainly by N-glycosylation, consistent
with four or two potential acceptor sites which are present in
the K1VI/V and K1V segments, respectively [12]. Fragment
K1V formed 10 nm long rods, which is in agreement with
the crystal structure of three LE modules of the laminin Q1
chain [26]. Fragment K1VI/V showed an additional globular
domain, consistent with previous interpretations of the lami-
nin structure [5,6]. Yet we failed to produce this globular
domain VI alone, indicating that the LN module has no
autonomous folding properties and gets rapidly degraded, as
found for other recombinant deletion fragments [27]. This was
a surprising observation, since single LE [11], and globular L4
[28] and LG [29] modules of laminins can be readily obtained
by the same recombinant procedures. In recent experiments,
however, we also failed to prepare LN modules of the laminin
L1 and Q1 chains (T. Sasaki and R. Timpl, unpublished) and
thus imperfect folding could be a general feature. Apparently,
more than one single adjacent LE module seems to be re-
quired to initiate folding and/or stabilization of LN modules.
Despite the failure to obtain the LN module for binding
studies, a comparison of the activities of fragments K1VI/V
and K1V localized heparin, perlecan and integrin binding to
the LN module. Heparin binding had a salt sensitivity (0.3 M
NaCl) clearly above physiological levels and comparable to
that of fragment E3, which was previously considered to rep-
resent the major binding site of laminin-1 for heparin and
perlecan [17,25,30]. A somewhat weaker heparin a⁄nity
(0.18 M NaCl) was also observed for a larger related K1 chain
fragment (K1VI-IVb) and attributed to the LN module [10].
Here we also showed that the two perlecan fragments IA and
Vc, when substituted with heparan sulfate chains [18,19],
bound with comparable a⁄nities (Kd = 5^7 nM) to fragment
K1VI/V at physiological salt concentration. These perlecan
binding domains, as well as the corresponding laminin K1
chain binding epitopes, are located at opposite ends of the
proteins. This raises the possibility that they could form
linear copolymers which may contribute to basement
membrane structure. A brief elastase digestion of frag-
ment K1VI/V apparently cleaved a single peptide bond at
position 224/225 in the LN module but did not in£uence hep-
arin binding of either fragment. The regions £anking the
cleavage site, RYIRLRLQRIR (positions 205^215) and
RDLRDLDPIVTRRYYYSIK (positions 227^245), are rich
in basic amino acid residues and their loss upon more exten-
sive digestion abolished heparin binding. This indicated that
both regions, together or individually, contribute to one or
two binding epitopes.
Another major activity of the LN module is involvement in
cell adhesion, as indicated from the binding of puri¢ed K1L1
and K2L1 integrins to laminin fragment E1XNd [9] and, for
K1L1 integrin, from cell adhesion and antibody inhibition
studies [10]. Here we showed distinct divalent cation-depend-
ent binding of both integrins to fragment K1VI/V, with a ¢ve-
fold di¡erence in a⁄nity, while no binding occurred to frag-
ment K1V. For K2L1 integrin, the same a⁄nity was found in
previous studies with laminin-1 and fragment E1XNd [9],
demonstrating that the recombinant fragment possesses a
fully active binding epitope. The K1L1 and K2L1 integrins
were originally identi¢ed as major receptors for several colla-
gen types [31,32] but they have also been shown to bind to
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Table 1
Binding of immobilized laminin fragment K1VI/V to integrin and perlecan ligands in surface plasmon resonance assays
Soluble ligands kdissU103 kassU1033 Kd
(s31) (M31 s31) (nM)
K1L1 integrin 0.36 40 9 þ 6
K2L1 integrin 1.4 31 45 þ 30
perlecan fragment IA 0.57 106 5.3 þ 0.8
perlecan fragment I-Mut no binding
perlecan fragment Vc 0.25 33 7.5 þ 1.2
perlecan fragment V no binding
perlecan fragment II no binding
perlecan fragment III-2 no binding
Average values of 3^4 independent determinations with S.D. values given for Kd.
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laminin-1, although with lower e⁄ciency [9]. As shown for
K1L1 integrin binding to collagen IV, the collagen epitope
requires a single Arg and two Asp residues to be ¢xed in
triple-helical conformation for proper binding [33]. The com-
plementary epitope on the integrins has been localized to the
A domain [34,35]. Based on the X-ray structure of the integrin
K2 chain A domain [36], it was speculated that a shallow
groove formed by the cation-binding MIDAS motif would
allow a collagen triple-helix to dock perfectly. Yet it is not
clear and hard to predict whether this binding epitope would
also ¢t a structure on the laminin K1 chain LN module. In
this context, however, it is of interest that the Kd values meas-
ured for the binding of the two A domains to collagen I [35]
are of the same order of magnitude and show the same di¡er-
ence between the two integrins as determined here for the
laminin fragment K1VI/V.
The present recombinant study has set the stage for exam-
ining the various binding properties of the laminin K1 chain
LN module, including its potential involvement in self-assem-
bly [6^8], by site-directed mutagenesis. The high production
rates will also make crystallization feasible, providing support
for epitope mapping.
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